Magnetic Marker Localization for Occult Breast Cancer and Target Axillary Dissection in Node-positive Breast Cancer Post-neoadjuvant Chemotherapy

The use of neoadjuvant chemotherapy in breast cancer is expanding in the recent decade. Patients with good response to neoadjuvant chemotherapy could benefit from de-escalation of breast and axilla operation. However, breast tumor and involved axillary lymph node should be marked before the commencement of chemotherapy. This could facilitate subsequent operative planning and intraoperative assessment of disease response. This study aims to evaluate the feasibility of magnetic marker localization for non-palpable breast cancer and targeted axillary dissection in patients with node-positive brea

Trial Details

NCT ID
NCT05427071
Phase
NA
Sponsor
The University of Hong Kong
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Magnetic seed localization
Locations (sample)
  • Hong Kong, Hong Kong|22.27832,114.17469

Key Eligibility Criteria

  • All patients with cT1-3N1 invasive ductal carcinoma planned for neoadjuvant chemotherapy and/or target therapy
  • mentally competent to give informed consent
  • Agreed to proceed with curative operation after chemotherapy and tentatively keen for breast conservative surgery and targeted axillary dissection …
  • Radiologically 1-3 ipsilateral axillary lymph node metastases confirmed by cytology or biopsy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →